Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors.
genetic counseling
genetic testing
genetics health professional
hereditary breast cancer
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
05
12
2019
accepted:
04
02
2020
revised:
29
01
2020
pubmed:
19
2
2020
medline:
28
4
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
All women diagnosed with breast cancer (BC) ≤age 50 should be referred for genetic counseling (GC) and testing. We sought to compare differences in provider practices and access across a racially and ethnically diverse population of young BC survivors. A registry-based sample of women diagnosed with invasive BC ≤age 50 from 2009 to 2012 was recruited through the Florida Cancer Registry, and completed a questionnaire and medical record release. Differences were compared across those tested with or without the involvement of a board-certified or credentialed genetics health professional (GHP) in (1) clinical and demographic variables and (2) pretest GC elements. Of 1622 participants, there were 440 Blacks, 285 Hispanics, and 897 Non-Hispanic Whites. Of 831 participants with medical record verification of testing provider, 170 (20%) had documentation of GHP involvement. Among the 613 who recalled a pretest discussion and had GC elements collected, those with GHP involvement were significantly more likely to recall the seven recognized GC elements. GHP involvement was associated with adherence to nationally recommended best practices. With the expanding importance of identifying inherited cancers, it is critical to ensure equitable access to best practices across all populations.
Identifiants
pubmed: 32066870
doi: 10.1038/s41436-020-0762-0
pii: S1098-3600(21)00833-9
pmc: PMC7275890
mid: NIHMS1572591
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1088-1093Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204819
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA160056
Pays : United States
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Clin J. 2018;68:394–424.
doi: 10.3322/caac.21492
Felix GES, Zheng Y, Olopade OI. Mutations in context: implications of BRCA testing in diverse populations. Fam Cancer. 2018;17:471–483.
doi: 10.1007/s10689-017-0038-2
Yedjou CG, Sims JN, Miele L, et al. Health and racial disparity in breast cancer. In: Ahmad A, editor. Breast cancer metastasis and drug resistance: challenges and progress. Cham, Switzerland: Springer; 2019. p. 31–49.
Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104:1384–1392.
doi: 10.1038/bjc.2011.120
Pierce LJ, Phillips K-A, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389–398.
doi: 10.1007/s10549-010-0894-z
Menes TS, Terry MB, Goldgar D, et al. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2015;151:653–660.
doi: 10.1007/s10549-015-3419-y
Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28:2404–2410.
doi: 10.1200/JCO.2009.24.2495
Salhab M, Bismohun S, Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Womens Health. 2010;10:28–28.
doi: 10.1186/1472-6874-10-28
Warner E. Screening BRCA1 and BRCA2 mutation carriers for breast cancer. Cancers (Basel). 2018;10:477.
doi: 10.3390/cancers10120477
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4:CD002748–CD002748.
National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian and pancreatic. (Version1.2020). https://www-nccn-org.proxy.library.vanderbilt.edu/ . Accessed 5 December 2019.
Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–161.
doi: 10.1007/s10897-011-9462-x
Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33:3660–3667.
doi: 10.1200/JCO.2015.63.0996
Penon-Portmann M, Chang J, Cheng M, Shieh JT. Genetics workforce: distribution of genetics services and challenges to health care in California. Genet Med. 2019;22:227–231.
doi: 10.1038/s41436-019-0628-5
Bookman T. More people seek genetic testing, but there aren’t enough counselors. http://www.npr.org/sections/health-shots/2016/04/18/473066953/more-people-seek-genetic-testing-but-there-arent-enough-counselors . Accessed 11 October 2016.
Bureau of Labor Statistics. Occupational employment statistics: occupational employment and wages, May 2016. 29-9092 Genetic counselors. https://www.bls.gov/oes/2016/may/oes299092.htm . Accessed 1 Nov 2019.
Villegas C, Haga SB. Access to genetic counselors in the Southern United States. J Pers Med. 2019;9:E33.
doi: 10.3390/jpm9030033
Hoskovec JM, Bennett RL, Carey ME, et al. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns. 2018;27:16–20.
doi: 10.1007/s10897-017-0158-8
Acheson LS, Stange KC, Zyzanski S. Clinical genetics issues encountered by family physicians. Genet Med. 2005;7:501–508.
doi: 10.1097/01.gim.0000177418.24176.9b
Vig HS, Armstrong J, Egleston BL, et al. Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers. 2009;13:735–741.
doi: 10.1089/gtmb.2009.0037
Radford C, Prince A, Lewis K, Pal T. Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. J Genet Couns. 2014;23:522–530.
doi: 10.1007/s10897-013-9668-1
Whitworth P, Beitsch P, Arnell C, et al. Impact of payer constraints on access to genetic testing. J Oncol Pract. 2017;13:e47–e56.
doi: 10.1200/JOP.2016.013581
Stenehjem DD, Au T, Sainski AM, et al. Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res. 2018;18:165.
doi: 10.1186/s12913-018-2957-5
Cragun D, Camperlengo L, Robinson E, et al. Differences in BRCA counseling and testing practices based on ordering provider type. Genet Med. 2015;17:51–57.
doi: 10.1038/gim.2014.75
Pal T, Rocchio E, Garcia A, Rivers D, Vadaparampil S. Recruitment of black women for a study of inherited breast cancer using a cancer registry–based approach. Genet Test Mol Biomarkers. 2010;15:69–77.
doi: 10.1089/gtmb.2010.0098
Bonner D, Pal T, Tallo C, Vadaparampil ST. Abstract A33: the utility of a state-wide cancer registry in recruiting a clinically representative population-based sample of young black women diagnosed with early-onset breast cancer. Cancer Epidemiol Biomarkers Prev. 2012;21 Suppl 10:A33–A33.
Cragun D, Weidner A, Lewis C, et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer. 2017;123:2497–2505.
doi: 10.1002/cncr.30621
Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35:2232–2239.
doi: 10.1200/JCO.2016.71.6480
Pal T, Radford C, Weidner A, Tezak AL, Cragun D, Wiesner GL. The Inherited Cancer Registry (ICARE) initiative: an academic-community partnership for patients and providers. Oncol Issues. 2018;33:54–63.
doi: 10.1080/10463356.2018.1525993
Bellcross CA, Leadbetter S, Alford SH, Peipins LA. Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev. 2013;22:728–735.
doi: 10.1158/1055-9965.EPI-12-1280
Hall M, Olopade OI. Confronting genetic testing disparities: knowledge is power. JAMA. 2005;293:1783–1785.
doi: 10.1001/jama.293.14.1783
Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011;13:349–355.
doi: 10.1097/GIM.0b013e3182091ba4
Katz SJ, Ward KC, Hamilton AS, et al. Gaps in receipt of clinically indicated genetic counseling after diagnosis of breast cancer. J Clin Oncol. 2018;36:1218–1224.
doi: 10.1200/JCO.2017.76.2369
Hull LE, Haas JS, Simon SR. Provider discussions of genetic tests with U.S. women at risk for a BRCA mutation. Am J Prev Med. 2018;54:221–228.
doi: 10.1016/j.amepre.2017.10.015
Cigna. Genetic testing and counseling resources. 2016. https://www.cigna.com/health-care-providers/resources/genetic-testing-and-counseling-program .
Scott D, Friedman S, Telli ML, Kurian AW. Decision making about genetic testing among women with a personal and family history of breast cancer. J Oncol Pract. 2019 Oct 15; doi:10.1200/JOP.19.00221 [Epub ahead of print].
Barcenas CH, Shafaee MN, Sinha AK, et al. Genetic counseling referral rates in long-term survivors of triple-negative breast cancer. J Natl Compr Canc Netw. 2018;16:518–524.
doi: 10.6004/jnccn.2018.7002
Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293:1729–1736.
doi: 10.1001/jama.293.14.1729
Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533.
doi: 10.1056/NEJMoa1706450
US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322:652–665.
doi: 10.1001/jama.2019.10987